

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Or, et al.
Serial No.: 09/800,856
Docket No.: ENP-019
Filing Date: 3/5/2001

Group Art Unit: 1614

Examiner: TBD

TITLE: Cyclosporins for the Treatment of Respiratory Diseases

Box Non-Fee Amendment
Commissioner for Patents
Washington, D.C. 20231

RECEIVED
FEB 19 2002
TECH CENTER 1600/2900


TRANSMITTAL LETTER

Dear Sir/Madam:

Enclosed herewith for filing in the above – referenced patent application are the following executed documents:

1. Change of Correspondence Address Application (PTO/SB/122);
2. Power of Attorney or Authorization of Agent (PTO/SB/81); and
3. Statement Under 37 CFR 3.73(b) (PTO/SB/96).


Respectfully submitted
ENANTA PHARMACEUTICALS, Inc.


Sandhya L. Kalkunte
Registration No. 46,466

January 30, 2002
Enanta Pharmaceuticals, Inc.
500 Arsenal Street
Watertown, MA 02472
Phone: (617) 607-0800
Fax: (617) 607-0535

Certificate of Mailing under 37 C.F.R. § 1.8(a)

I hereby certify that this correspondence is being deposited today with the United States Postal Service as First Class Mail in an envelope addressed to: Box Non-Fee Amendment, Commissioner for Patents, Washington, D.C. 20231.


Date: 1/30/02